This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 80% and 3.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 6.23% and 1.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cognizant (CTSH) Partners With Accuray to Improve Healthcare
by Zacks Equity Research
Cognizant's (CTSH) partnership agreement will enable Accuray to streamline and drive operational changes to improve patient care.
Accuray (ARAY) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Accuray's (ARAY) solid product portfolio.
Accuray (ARAY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal third-quarter top line on the back of robust segmental performances.
Accuray (ARAY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Accuray (ARAY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 200% and 6.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q1 Earnings Due on Apr 26: MMSI, CNMD & More
by Indrajit Bandyopadhyay
Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MMSI, CNMD, NVRO and ARAY are likely to have performed this time.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
Accuray (ARAY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.
Accuray (ARAY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 7.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bear of the Day: Fresenius Medical (FMS)
by David Bartosiak
Profit estimates are moving in the wrong direction.
Accuray's (ARAY) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Despite solid product demand, Accuray (ARAY) reports an overall soft Q1 performance.
Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of -500% and 8.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fresenius Medical's (FMS) Q3 Earnings and Revenues Top
by Zacks Equity Research
Fresenius Medical's (FMS) third-quarter revenues benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.
McKesson (MCK) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter 2023 results benefit from segmental growth.
Stryker's (SYK) Q3 Earnings Miss Estimates, Volume Improves
by Zacks Equity Research
Stryker's (SYK) third-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.
Ecolab (ECL) Q3 Earnings & Revenues Miss Mark, Margins Down
by Zacks Equity Research
Ecolab's (ECL) robust performance across all its segments drives its Q3 sales, despite business challenges.
DexCom (DXCM) Q3 Earnings Beat Estimates, Guidance Revised
by Zacks Equity Research
DexCom's (DXCM) third-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Baxter (BAX) Q3 Earnings Meet Estimates, Hilrom Adds $735 M
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.
Integra's (IART) Q3 Earnings Top, Gross Margin Declines
by Zacks Equity Research
Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.
Align Technology (ALGN) Q3 Earnings Lag Estimates, Margins Drop
by Zacks Equity Research
The volatility surrounding inflationary pressure, weaker consumer confidence and the lingering impacts of COVID-19 shutdowns continue to pose challenges for Align Technology (ALGN).
CONMED (CNMD) Down on In-Line Q3 Earnings & Lower 2022 View
by Zacks Equity Research
CONMED's (CNMD) adjusted third-quarter earnings reflect strong segmental performance. Unfavorable currency movement hurt sales growth. Inflationary or supply chain challenges hurt gross margin.
Thermo Fisher (TMO) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Robust demand for Thermo Fisher's (TMO) laboratory products and biopharma services buoys optimism. However, lower Life Sciences Solutions segment revenues in the third quarter disappoint.
Philips' (PHG) Q3 Earnings Down on Supply Chain Constraints
by Zacks Equity Research
Koninklijke Philips' (PHG) Q3 top and bottom-line results reflect the negative impact of supply chain constraints, COVID lockdowns in China and the Russia-Ukraine war.